Ibex Medical Analytics vs PathAI
Two of the strongest records in computational pathology, holding different kinds of regulatory standing. Ibex detects cancer with prostate, breast and gastric solutions in routine clinical use, United States clearance as an in vitro diagnostic for the prostate product, peer reviewed publication and the most complete published certification set of any vendor in this index. PathAI covers more of the workflow, with clearance for an image management system for primary diagnosis, a large interpretation module portfolio, a drug development tool qualification and a model change plan a regulator has already reviewed. For a laboratory buying detection with the strongest assurance record behind it, Ibex. For one that wants the platform, the modules and a governed update path from one vendor, PathAI reaches further.
- The certification set is the most complete of any vendor in this index and its deployment evidence is verifiable through third parties.
- Three cancer types are in routine clinical use worldwide with peer reviewed publication behind the deployment scale.
- The cleared indication is conservative and well constructed, which is the right posture for software flagging cancer on a slide a pathologist signs.
- The regulatory portfolio is broader, including clearance for an image management system for primary diagnosis alongside a large set of interpretation modules.
- A drug development tool qualification put one of its models through a review process almost nothing else here has faced.
- Model change is governed by a plan a regulator has reviewed, which is a stronger mechanism than a published principles page.
Side by Side
| Axis | I Ibex Medical Analytics |
P PathAI |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
The regulatory positions are not equivalent and should not be read as competing claims of being first: one holds an in vitro diagnostic clearance for cancer detection in a specific tissue, the other holds clearance for an image management system plus a qualification under a separate regime. Neither publishes pricing. Neither publishes a bias evaluation or site level performance, and staining and scanner variation across laboratories affects model output before any patient variable does.